Type 1 diabetes

Association between worsening time in range and microvascular complications in type 1 diabetes: real-world 5-year study

J Clin Endocrinol MetabPublished Longitudinal real-world cohort study

Authors' conclusion

CGM-derived glucometrics were associated with the 5-year incidence of microvascular complications in this real-world cohort, with ΔTIR potentially providing additional prognostic information beyond HbA1c.

Study context

Population
Adults with T1D, tertiary referral center; median age 40 [28–53] years, diabetes duration 24 [13–33] years
Participants
246 adults
Exposure
Change in time in range (TIR) over follow-up: ≥10% decrease vs stable vs ≥10% increase
Outcome
Composite microvascular endpoint:
  • Nephropathy (persistent albuminuria ≥20 µg/min, eGFR <60 mL/min/1.73 m², and/or RAAS inhibitor use for albuminuria)
  • Severe retinopathy (proliferative retinopathy, maculopathy, and/or blindness)
  • Peripheral neuropathy (monofilament score <6/6 and/or abnormal nerve conduction)
Follow-up
5 years
Methodological detailsfive-year follow-up, tertiary referral center
  • Five-year follow-up
  • Tertiary referral center

Main finding

As reported in the abstract

Composite microvascular complication rate by change in TIR

P = 0.011

Observational data: associations, not effects.

Further findings

HbA1c over follow-up

HbA1c decreased from 7.6% (59 mmol/mol) to 7.2% (55 mmol/mol)

TIR (70-180 mg/dL) over follow-up

TIR increased from 50 ± 14% to 61 ± 15%

Other predictors

BMI and systolic blood pressure were not significant

Discrimination of models with glucometrics and age

AUCs
0.757-0.787
  • Acceptable discriminative performance

Original publication

Association between worsening time in range and microvascular complications in type 1 diabetes: real-world 5-year study. J Clin Endocrinol Metab. Published 16 September 2026. doi:10.1210/clinem/dgag380

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.